Qiagen NV (QGEN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $10.29B
Last updated: Nov 17, 2026 at 4:10 PM ET
Qiagen NV (QGEN) Statistics
Qiagen NV (QGEN) has a market cap of $10.29B and an enterprise value of $11.12B. Its share count is down 4.76% from a year earlier. Its return on invested capital of 8.20% compares with a 3.09% median across 8 similar companies.
Total Valuation
Enterprise value is 8.14% above the market cap, as debt exceeds cash.
| Market Cap | $10.29B |
|---|---|
| Enterprise Value | $11.12B |
| Latest price (Nov 17, 2026) | $49.75 |
Key Dates
The next earnings report is expected on Feb 2, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Jul 7, 2026.
| Next Earnings Date | Feb 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Last Ex-Dividend Date | Jul 7, 2026 |
| Last Payment Date | Jul 14, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 4.9x and 3.0x. Its year-end P/E ranged from 18.2x to 23.0x from 2016 to 2025.
| P/E Ratio | 20.5x |
|---|---|
| Forward P/E | 19.8x |
| P/S Ratio | 4.9x |
| Forward P/S | 4.8x |
| P/B Ratio | 3.0x |
| P/TBV Ratio | 22.2x |
| P/FCF Ratio | 23.8x |
| P/OCF Ratio | 16.2x |
| PEG Ratio | 3.3 |
Enterprise Valuation
Counting debt and cash, the company is valued at 15.9x EBITDA and 25.8x free cash flow.
| EV / Earnings | 28.9x |
|---|---|
| EV / Sales | 5.3x |
| EV / EBITDA | 15.9x |
| EV / EBIT | 22.2x |
| EV / FCF | 25.8x |
Price Statistics
The stock is up 11.68% over 52 weeks and trades 6.35% above its 50-day average.
| Beta (1Y) | 0.40 |
|---|---|
| 52-Week Change | +11.68% |
| 1-Month Change | +6.87% |
| 3-Month Change | +11.80% |
| 6-Month Change | +46.61% |
| 5-Year Change | -9.94% |
| 10-Year Change | +105.99% |
| Total Return (1Y) | +17.61% |
| Total Return (3Y CAGR) | +8.07% |
| Total Return (5Y CAGR) | -2.38% |
| Return vs SPY (1Y) | +0.04% |
| Max Drawdown (1Y) | -41.90% |
| Max Drawdown (3Y) | -41.90% |
| Sharpe Ratio (1Y) | 0.32 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $46.78 |
| 200-Day Average | $42.24 |
| 52-Week Range | $32.24 to $57.30 |
| RSI (14 Days) | 58.7 |
| Average Volume (20 Days) | 6.31M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.63x current liabilities, and total debt is 0.47x shareholder equity.
| Current Ratio | 2.63x |
|---|---|
| Quick Ratio | 2.14x |
| Debt / Equity | 0.47x |
| Debt / EBITDA | 2.33x |
| Debt / FCF | 3.78x |
| Interest Coverage | 12.02x |
Returns and Efficiency
Return on invested capital is 8.20% over the last 12 months, against a 5-year average of 6.95%.
| Return on Equity (ROE) | 11.08% |
|---|---|
| Return on Assets (ROA) | 6.48% |
| Return on Invested Capital (ROIC) | 8.20% |
| Return on Capital Employed (ROCE) | 9.48% |
| ROE (5Y Average) | 10.26% |
| ROA (5Y Average) | 5.77% |
| ROIC (5Y Average) | 6.95% |
| Asset Turnover | 0.34x |
| Inventory Turnover | 2.52x |
| Receivables Turnover | 5.36x |
| Cash Conversion Cycle | 170 days |
Taxes
Income tax took 16.21% of pretax income over the last 12 months.
| Income Tax (TTM) | $74.48M |
|---|---|
| Effective Tax Rate | 16.21% |
Scores
QGEN has an Altman Z-Score of 4.05, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.05 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $2.12B over the last 12 months is up 2.17% from the 12 months before.
| Revenue | $2.12B |
|---|---|
| Revenue Growth (YoY) | +2.17% |
| Gross Profit | $1.32B |
| Operating Income | $554.57M |
| Pretax Income | $459.42M |
| Net Income | $384.93M |
| EBITDA | $705.36M |
| EBIT | $501.12M |
| Reported EPS (TTM) | $2.43 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 58.42% of the $5.94B in total assets.
| Cash and Equivalents | $805.13M |
|---|---|
| Total Debt | $1.64B |
| Net Debt | $837.72M |
| Net Debt Per Share | $4.03 |
| Working Capital | $1.07B |
| Shareholder Equity | $3.47B |
| Book Value Per Share | $16.70 |
| Tangible Book Value | $465.88M |
| Tangible Book Per Share | $2.24 |
| Total Assets | $5.94B |
| Total Liabilities | $2.47B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $200.76M of capital spending, operating cash flow left $434.32M of free cash flow.
| Operating Cash Flow | $635.08M |
|---|---|
| Capital Expenditures | $200.76M |
| Free Cash Flow | $434.32M |
| FCF Per Share | $2.10 |
| Depreciation and Amortization | $204.24M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 26.21%, against a 5-year average of 20.70%.
| Gross Margin | 62.45% |
|---|---|
| Operating Margin | 26.21% |
| Pretax Margin | 21.72% |
| Net Margin | 18.19% |
| EBITDA Margin | 33.34% |
| EBIT Margin | 23.69% |
| FCF Margin | 20.53% |
| Gross Margin (5Y Average) | 60.51% |
| Operating Margin (5Y Average) | 20.70% |
| Net Margin (5Y Average) | 16.89% |
Growth
Revenue fell 0.81% a year over 3 years, and EPS 2.19% a year.
| Revenue Growth (3Y CAGR) | -0.81% |
|---|---|
| Revenue Growth (5Y CAGR) | +2.25% |
| EPS Growth (3Y CAGR) | -2.19% |
| EPS Growth (5Y CAGR) | +0.58% |
| FCF Growth (3Y CAGR) | -7.13% |
| FCF Growth (5Y CAGR) | +19.24% |
| Operating Income Growth (3Y CAGR) | -0.70% |
| Book Value Per Share Growth (2Y CAGR) | +3.39% |
| Tangible Book Per Share Growth (2Y CAGR) | -3.84% |
Dividends and Yields
QGEN pays out 18.92% of earnings as dividends.
| Dividend Per Share (Annual) | $0.35 |
|---|---|
| Dividend Yield | 0.70% |
| Payment Schedule | Annual |
| Payout Ratio | 18.92% |
| Earnings Yield | 4.88% |
| FCF Yield | 4.20% |
| Shareholder Yield | 4.04% |
Stock Splits
The last split was a 4-for-1 forward split on Jul 14, 2000.
| Last Split Date | Jul 14, 2000 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 4:1 |
Peer Position
Against 10 similar companies, QGEN has the 10th highest P/E.
P/E RatioPeer median 33.8x
P/S RatioPeer median 4.8x
ROICPeer median 3.09%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.11%
Dividend YieldPeer median 0.00%
| P/E Ratio | 20.5x vs 33.8x median |
|---|---|
| P/S Ratio | 4.9x vs 4.8x median |
| ROIC | 8.20% vs 3.09% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +2.17% vs +10.11% median |
| Dividend Yield | 0.70% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 3.65% and EPS growth at 3.94% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +3.65% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +3.94% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About QGEN
What is QGEN's market cap?
Qiagen NV has a market cap of $10.29B. Its enterprise value, which adds debt and subtracts cash, is $11.12B.
What is QGEN's P/E ratio?
Qiagen NV has a trailing P/E ratio of 20.5x and a forward P/E of 19.8x.
How many shares of QGEN are outstanding?
Qiagen NV has 208.06M shares outstanding. The count is down 4.76% from a year earlier.
Does QGEN pay a dividend?
Yes. Qiagen NV pays $0.35 a share a year, a dividend yield of 0.70%.
How much debt does QGEN have?
Qiagen NV has $1.64B of total debt and $805.13M of cash and equivalents, a net debt position of $837.72M.
QGEN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts